Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Total debt
Bio-Techne Corp's total debt at the end of fiscal 2026 was $200.0M, down 42.2% from $346.0M in fiscal 2025. Over the past ten years it has ranged from $73.0M (fiscal 2015) to $505.2M (fiscal 2019); the current reading is higher than 25% of that period. Bio-Techne Corp ranks 57th of 588 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2026 | $200.0M | (42.20%) |
| FY2025 | $346.0M | 8.46% |
| FY2024 | $319.0M | (8.86%) |
| FY2023 | $350.0M | 36.77% |
| FY2022 | $255.9M | (25.02%) |
| FY2021 | $341.3M | (4.32%) |
| FY2020 | $356.7M | (29.38%) |
| FY2019 | $505.2M | 49.01% |
| FY2018 | $339.0M | (1.39%) |
| FY2017 | $343.8M | 259.97% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $200.0M | 0.00% |
| Mar 2026 | $200.0M | (23.08%) |
| Dec 2025 | $260.0M | (13.33%) |
| Sep 2025 | $300.0M | (13.29%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $4.2B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| IBRX ImmunityBio, Inc. compare | $774.4M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $340.8M |
| TECH Bio-Techne Corp | $200.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
| PCVX Vaxcyte, Inc. compare | $14.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| CORT Corcept Therapeutics Incorporated compare | $5.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement